Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Preclinical Efficacy and Biological Effects of Venetoclax and Ixazomib in Combination in Lymphoma Cells

Maria Cosenza, MS, Stefano Sacchi, MD, Samantha Pozzi, MD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-134882

Published: 2020

Journal Articles

Combination of Momelotinib and Citarinostat Show Strong Synergistic Effect in Lymphoid Cell Lines Co-Targeting JAK2/STAT3 and HDAC6

Maria Cosenza, MS, Monica Civallero, PhD, Stefano Sacchi, MD, Samantha Pozzi, MD

Blood (2018) 132 (Supplement 1): 3506.

https://doi.org/10.1182/blood-2018-99-116468

Published: 2018

Journal Articles

Ruxolitinib in Combination with Vorinostat Suppresses Tumor Growth and Alters the Metabolic Phenotype in Haematological Diseases

Monica Civallero, PhD, Maria Cosenza, MS, Sandra Marmiroli, MS, Samantha Pozzi, MD, Stefano Sacchi, MD

Blood (2017) 130 (Supplement 1): 5194.

https://doi.org/10.1182/blood.V130.Suppl_1.5194.5194

Published: 2017

Journal Articles

Momelotinib and Citarinostat: Co-Targeting JAK2/STAT3 and HDAC6 in Lymphoid Malignancies, a New Potential Therapeutic Combination

Maria Cosenza, MS, Monica Civallero, PhD, Stefano Sacchi, MD, Samantha Pozzi, MD

Blood (2017) 130 (Supplement 1): 5201.

https://doi.org/10.1182/blood.V130.Suppl_1.5201.5201

Published: 2017

Journal Articles

Romidepsin and Lenalidomide Show a Synergistic Effect In T–Cell Lymphoma Cell Lines

Maria Cosenza, MS, Monica Civallero, MS, PhD, Stefania Fiorcari, MS, Samantha Pozzi, MD, Luigi Marcheselli, Eliana Valentina Liardo, MD, Alessia Bari, MD, Stefano Sacchi, MD

Blood (2013) 122 (21): 5148.

https://doi.org/10.1182/blood.V122.21.5148.5148

Published: 2013

Journal Articles

In Vitro Combination of Bortezomib with Enzastaurin or Lenalidomide Enhances the Cytotoxicity in B-Cell Lymphoma Cell Lines.

Maria Cosenza, MS, Monica Civallero, MS, PhD, Samantha Pozzi, Alessia Bari, MD, Eliana Valentina Liardo, Stefano Sacchi

Blood (2012) 120 (21): 2754.

https://doi.org/10.1182/blood.V120.21.2754.2754

Published: 2012

NARROW

Preclinical Efficacy and Biological Effects of Venetoclax and Ixazomib in Combination in Lymphoma Cells

Combination of Momelotinib and Citarinostat Show Strong Synergistic Effect in Lymphoid Cell Lines Co-Targeting JAK2/STAT3 and HDAC6

Ruxolitinib in Combination with Vorinostat Suppresses Tumor Growth and Alters the Metabolic Phenotype in Haematological Diseases

Momelotinib and Citarinostat: Co-Targeting JAK2/STAT3 and HDAC6 in Lymphoid Malignancies, a New Potential Therapeutic Combination

Romidepsin and Lenalidomide Show a Synergistic Effect In T–Cell Lymphoma Cell Lines

In Vitro Combination of Bortezomib with Enzastaurin or Lenalidomide Enhances the Cytotoxicity in B-Cell Lymphoma Cell Lines.

Email alerts

ASH Publications

American Society of Hematology

Preclinical Efficacy and Biological Effects of Venetoclax and Ixazomib in Combination in Lymphoma Cells

Combination of Momelotinib and Citarinostat Show Strong Synergistic Effect in Lymphoid Cell Lines Co-Targeting JAK2/STAT3 and HDAC6

Ruxolitinib in Combination with Vorinostat Suppresses Tumor Growth and Alters the Metabolic Phenotype in Haematological Diseases

Momelotinib and Citarinostat: Co-Targeting JAK2/STAT3 and HDAC6 in Lymphoid Malignancies, a New Potential Therapeutic Combination

Romidepsin and Lenalidomide Show a Synergistic Effect In T–Cell Lymphoma Cell Lines

In Vitro Combination of Bortezomib with Enzastaurin or Lenalidomide Enhances the Cytotoxicity in B-Cell Lymphoma Cell Lines.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only